Vimarsana
Biggest News Aggregation in the World

Page 8 - Nasdaq Coll News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Coll. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Coll Today - Breaking & Trending Today

Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at StockNews.com - Vimarsana News

Collegium Pharmaceutical (NASDAQ:COLL) Cut to "Hold" at StockNews.com

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a buy rating to a hold rating in a research note released on Tuesday morning. Other equities research analysts also recently issued research reports about the stock. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a […]

Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com - Vimarsana News

Collegium Pharmaceutical (NASDAQ:COLL) Downgraded by StockNews.com

StockNews.com cut shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a buy rating to a hold rating in a report published on Tuesday. COLL has been the topic of a number of other reports. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a research note on […]

Source: wkrb13.com
Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Hold at StockNews.com - Vimarsana News

Collegium Pharmaceutical (NASDAQ:COLL) Lowered to Hold at StockNews.com

Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday. Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 target […]

Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at StockNews.com - Vimarsana News

Collegium Pharmaceutical (NASDAQ:COLL) Upgraded at StockNews.com

StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a hold rating to a buy rating in a report issued on Monday morning. Several other analysts have also recently issued reports on COLL. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a research note on […]

Source: wkrb13.com
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post Q1 2023 Earnings of $1.00 Per Share, Jefferies Financial Group Forecasts - Vimarsana News

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to Post Q1 2023 Earnings of $1.00 Per Share, Jefferies Financial Group Forecasts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for Collegium Pharmaceutical in a report issued on Tuesday, May 2nd. Jefferies Financial Group analyst G. Santangelo anticipates that the specialty pharmaceutical company will post earnings of $1.00 per share for the […]

Source: wkrb13.com